|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAB9A |
Gene summary for RAB9A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAB9A | Gene ID | 9367 |
| Gene name | RAB9A, member RAS oncogene family | |
| Gene Alias | RAB9 | |
| Cytomap | Xp22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024RBV5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9367 | RAB9A | LZE4T | Human | Esophagus | ESCC | 9.61e-11 | 3.49e-01 | 0.0811 |
| 9367 | RAB9A | LZE7T | Human | Esophagus | ESCC | 2.47e-08 | 5.35e-01 | 0.0667 |
| 9367 | RAB9A | LZE8T | Human | Esophagus | ESCC | 9.01e-14 | 5.78e-01 | 0.067 |
| 9367 | RAB9A | LZE20T | Human | Esophagus | ESCC | 9.40e-06 | 3.53e-01 | 0.0662 |
| 9367 | RAB9A | LZE22T | Human | Esophagus | ESCC | 2.05e-05 | 4.18e-01 | 0.068 |
| 9367 | RAB9A | LZE24T | Human | Esophagus | ESCC | 8.42e-16 | 3.61e-01 | 0.0596 |
| 9367 | RAB9A | LZE21T | Human | Esophagus | ESCC | 7.35e-04 | 4.50e-01 | 0.0655 |
| 9367 | RAB9A | LZE6T | Human | Esophagus | ESCC | 8.01e-12 | 9.50e-01 | 0.0845 |
| 9367 | RAB9A | P1T-E | Human | Esophagus | ESCC | 1.48e-05 | 5.61e-01 | 0.0875 |
| 9367 | RAB9A | P2T-E | Human | Esophagus | ESCC | 4.57e-37 | 7.77e-01 | 0.1177 |
| 9367 | RAB9A | P4T-E | Human | Esophagus | ESCC | 1.46e-20 | 7.33e-01 | 0.1323 |
| 9367 | RAB9A | P5T-E | Human | Esophagus | ESCC | 1.21e-19 | 3.31e-01 | 0.1327 |
| 9367 | RAB9A | P8T-E | Human | Esophagus | ESCC | 2.20e-39 | 9.12e-01 | 0.0889 |
| 9367 | RAB9A | P9T-E | Human | Esophagus | ESCC | 1.52e-17 | 2.35e-01 | 0.1131 |
| 9367 | RAB9A | P10T-E | Human | Esophagus | ESCC | 1.33e-22 | 1.63e-01 | 0.116 |
| 9367 | RAB9A | P11T-E | Human | Esophagus | ESCC | 7.60e-18 | 7.58e-01 | 0.1426 |
| 9367 | RAB9A | P12T-E | Human | Esophagus | ESCC | 5.98e-20 | 3.95e-01 | 0.1122 |
| 9367 | RAB9A | P15T-E | Human | Esophagus | ESCC | 8.74e-22 | 4.56e-01 | 0.1149 |
| 9367 | RAB9A | P16T-E | Human | Esophagus | ESCC | 3.96e-26 | 5.28e-01 | 0.1153 |
| 9367 | RAB9A | P17T-E | Human | Esophagus | ESCC | 1.19e-05 | 3.32e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:001648210 | Esophagus | ESCC | cytosolic transport | 124/8552 | 168/18723 | 9.69e-14 | 4.69e-12 | 124 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| GO:00421477 | Esophagus | ESCC | retrograde transport, endosome to Golgi | 63/8552 | 91/18723 | 4.58e-06 | 4.87e-05 | 63 |
| GO:005181714 | Esophagus | ESCC | modulation of process of other organism involved in symbiotic interaction | 54/8552 | 81/18723 | 1.09e-04 | 7.64e-04 | 54 |
| GO:003582114 | Esophagus | ESCC | modulation of process of other organism | 64/8552 | 106/18723 | 1.61e-03 | 7.50e-03 | 64 |
| GO:00518171 | Liver | Cirrhotic | modulation of process of other organism involved in symbiotic interaction | 44/4634 | 81/18723 | 1.11e-08 | 4.26e-07 | 44 |
| GO:001648211 | Liver | Cirrhotic | cytosolic transport | 74/4634 | 168/18723 | 3.34e-08 | 1.12e-06 | 74 |
| GO:001619711 | Liver | Cirrhotic | endosomal transport | 93/4634 | 230/18723 | 1.01e-07 | 2.93e-06 | 93 |
| GO:00358213 | Liver | Cirrhotic | modulation of process of other organism | 49/4634 | 106/18723 | 1.20e-06 | 2.43e-05 | 49 |
| GO:000726511 | Liver | Cirrhotic | Ras protein signal transduction | 119/4634 | 337/18723 | 8.16e-06 | 1.22e-04 | 119 |
| GO:004214711 | Liver | Cirrhotic | retrograde transport, endosome to Golgi | 34/4634 | 91/18723 | 5.01e-03 | 2.60e-02 | 34 |
| GO:001619721 | Liver | HCC | endosomal transport | 154/7958 | 230/18723 | 4.74e-14 | 2.95e-12 | 154 |
| GO:001648221 | Liver | HCC | cytosolic transport | 117/7958 | 168/18723 | 8.83e-13 | 4.48e-11 | 117 |
| GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
| GO:00518172 | Liver | HCC | modulation of process of other organism involved in symbiotic interaction | 56/7958 | 81/18723 | 1.11e-06 | 1.65e-05 | 56 |
| GO:004214721 | Liver | HCC | retrograde transport, endosome to Golgi | 61/7958 | 91/18723 | 1.94e-06 | 2.68e-05 | 61 |
| GO:003582111 | Liver | HCC | modulation of process of other organism | 67/7958 | 106/18723 | 1.34e-05 | 1.48e-04 | 67 |
| GO:00161979 | Oral cavity | OSCC | endosomal transport | 141/7305 | 230/18723 | 5.40e-12 | 2.06e-10 | 141 |
| GO:00164829 | Oral cavity | OSCC | cytosolic transport | 106/7305 | 168/18723 | 2.08e-10 | 5.90e-09 | 106 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa0513222 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
| hsa0513232 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
| hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
| hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
| hsa0513230 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa051628 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa0516212 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa05132210 | Oral cavity | LP | Salmonella infection | 128/2418 | 249/8465 | 1.17e-14 | 2.79e-13 | 1.80e-13 | 128 |
| hsa0516221 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
| hsa0513238 | Oral cavity | LP | Salmonella infection | 128/2418 | 249/8465 | 1.17e-14 | 2.79e-13 | 1.80e-13 | 128 |
| hsa0516231 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
| hsa0513228 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
| hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa05132113 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
| hsa0516211 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAB9A | SNV | Missense_Mutation | c.142G>T | p.Asp48Tyr | p.D48Y | P51151 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| RAB9A | SNV | Missense_Mutation | c.509G>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| RAB9A | SNV | Missense_Mutation | c.391N>T | p.Arg131Trp | p.R131W | P51151 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| RAB9A | insertion | Frame_Shift_Ins | novel | c.169_170insATCTCAAAAG | p.Thr57AsnfsTer28 | p.T57Nfs*28 | P51151 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RAB9A | SNV | Missense_Mutation | c.127N>A | p.Glu43Lys | p.E43K | P51151 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RAB9A | SNV | Missense_Mutation | c.201N>T | p.Glu67Asp | p.E67D | P51151 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAB9A | SNV | Missense_Mutation | c.509N>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAB9A | SNV | Missense_Mutation | novel | c.77N>T | p.Arg26Ile | p.R26I | P51151 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAB9A | SNV | Missense_Mutation | c.509N>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAB9A | SNV | Missense_Mutation | c.509N>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | NSC-234945 | CHEMBL260311 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | CID 838877 | CHEMBL405317 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | TDR77585 | CHEMBL1333386 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | DNDI1417031 | CHEMBL1333049 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | CID 660258 | CHEMBL259805 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | 2-AMINO-ANTHRAQUINONE | CHEMBL84685 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | CID 887167 | CHEMBL260342 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | 7-HYDROXY ISOFLAVONE | 7-HYDROXY ISOFLAVONE | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | LASSBIO-123 | CHEMBL573111 | ||
| 9367 | RAB9A | ENZYME, DRUGGABLE GENOME | VU0080241 | CHEMBL477396 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |